
Search Clinical Trials
Sponsor Condition of Interest |
---|
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutan1
Melanoma and Skin Cancer Trials Limited
Cutaneous Melanoma, Stage II
Patients with a primary invasive melanoma are recommended to undergo excision of the
primary lesion with a wide margin. There is evidence that less radical margins of
excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm
margin of excision of the primary lesion for1 expand
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life. Type: Interventional Start Date: Dec 2019 |
Exercise and Emotional Learning in Posttraumatic Stress Disorder
Christal L Badour
PTSD
The goal of this clinical trial is to test how exercise affects learning and memory
processes relevant to the treatment of PTSD. Participants will complete a baseline intake
followed by two experimental sessions. During the first experimental session,
participants will undergo an MRI session of ima1 expand
The goal of this clinical trial is to test how exercise affects learning and memory processes relevant to the treatment of PTSD. Participants will complete a baseline intake followed by two experimental sessions. During the first experimental session, participants will undergo an MRI session of imaginal exposure to traumatic memory cues followed by 30-minutes of moderate intensity exercise or low intensity exercise. Participants will complete a second session of imaginal exposure with MRI 24 hours later. Type: Interventional Start Date: May 2024 |
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual1
Timothy Mullett
Non-Small Cell Lung Cancer
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for
patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV
Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their
cancer. expand
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer. Type: Interventional Start Date: Apr 2022 |
Cervical Cancer Prevention for Black Adults
Adebola Adegboyega
Cervical Cancer
The goal of this study is to develop and pilot test an intervention, entitled Health is
Wealth: A Cervical Health Program, designed to promote screening and reduce perceived
barriers to Cervical Cancer (CC) screening.
Aim 1: Examine general awareness and cultural factors (fatalism,
religiosity/spi1 expand
The goal of this study is to develop and pilot test an intervention, entitled Health is Wealth: A Cervical Health Program, designed to promote screening and reduce perceived barriers to Cervical Cancer (CC) screening. Aim 1: Examine general awareness and cultural factors (fatalism, religiosity/spirituality, temporal orientation, medical mistrust, and acculturation) related to cancer control and prevention among African Americans (AA) and Sub Saharan African (SAI) Immigrants. Aim 2: Examine the socioecological barriers and facilitators to CC screening and self-sampling to inform tailoring of an evidenced based cervical health program to promote CC screening. Aim 3: Assess feasibility, acceptability, and preliminary efficacy in a pilot test of the Health is Wealth: A Cervical Health Program among 30 AA and 30 SAI women using quasi-experimental design. This study will take place in 2 phases. Type: Interventional Start Date: Jan 2023 |
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple1
Caribou Biosciences, Inc.
Relapsed/Refractory Multiple Myeloma
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an
allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell
maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the
effectiveness of CB-011 in treating multiple myelom1 expand
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory). Type: Interventional Start Date: Feb 2023 |
Flat Dose Vs. Weight-based IP Chemotherapy for CRS/HIPEC
Prakash Pandalai
Peritoneal Carcinomatosis
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically
been associated with poor overall survival (≤ 12 months) with few treatment options.
Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules,
combined with direct administration of hea1 expand
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options. Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal carcinomatosis. IP chemotherapy allows delivery of a high dose of cytostatic drug directly onto the peritoneal surfaces at risk for microscopic residual disease while systemic exposure remains limited. Additionally, hyperthermia is known to enhance the cytotoxicity of several agents (including Mitomycin C) and improves the depth of peritoneal penetration. This trial will be a randomized phase 2 comparison of flat dose versus weight-based dose Mitomycin C. The hypothesis of this study is that HIPEC weight-based dosing may result in similarly effective peritoneal Mitomycin C concentrations with less systemic absorption and potential systemic toxicity, compared with the HIPEC flat dosing approach in patients undergoing CRS/HIPEC. Type: Interventional Start Date: Jun 2021 |
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Ly1
Caribou Biosciences, Inc.
Lymphoma, Non-Hodgkin
Relapsed Non Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Non Hodgkin Lymphoma
Lymphoma
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and
immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma
after lymphodepletion consisting of cyclophosphamide and fludarabine. expand
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine. Type: Interventional Start Date: May 2021 |
CERAMENT™| Bone Void Filler Device Registry
BONESUPPORT AB
Orthopedic Disorder
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in
normal use. expand
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal use. Type: Observational [Patient Registry] Start Date: Mar 2020 |
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Exte1
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3 expand
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3 Type: Interventional Start Date: Aug 2021 |
- Previous
- Next